EPRX Eupraxia Pharmaceuticals Inc.
Fundamentals / CIK 0001581178 / USDEupraxia Pharmaceuticals Inc. reported $0 in revenue and a net loss of $38.58M for the fiscal year ended December 31, 2025.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open EPRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$0 Dec 31, 2025
-
Operating Income FY 2025-$38.43M Operating profit
-
Net Income FY 2025-$38.58M GAAP bottom line
-
Diluted EPS FY 2025-$1.03 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Dec 31, 2025$80.56M Total debt: $154K
Annual revenue and net income
4 fiscal years (2022 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -- |
| Research & Development | $21.33M | $16.08M | $20.36M | $13.63M |
| Total Operating Expenses | $38.43M | $27.00M | $27.85M | $17.62M |
| Operating Income | -$38.43M | -$27.00M | -$27.85M | -$17.62M |
| EBITDA | -$38.20M | -$26.83M | -$27.69M | -$17.47M |
| Interest Income | $1.41M | $1.16M | $863K | $432K |
| Interest Expense | $0 | $604K | $1.17M | $983K |
| Income Before Tax | -$38.59M | -$25.74M | -$28.93M | -$18.99M |
| Income Tax Expense | $19K | $1.8K | $36K | $0 |
| Net Income | -$38.58M | -$25.50M | -$28.22M | -$18.49M |
| Basic EPS | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Diluted EPS | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Basic Shares Outstanding | 40.0M | 33.9M | 24.1M | 19.3M |
| Diluted Shares Outstanding | 40.0M | 33.9M | 24.1M | 19.3M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| Cash & Short-Term Investments | $80.56M | $33.10M | $19.34M | $18.26M |
| Accounts Receivable, Net | $716K | $258K | $154K | -- |
| Total Current Assets | $85.10M | $34.44M | $19.80M | $18.59M |
| Property, Plant & Equipment, Net | $834K | $358K | $410K | $443K |
| Total Non-Current Assets | $1.05M | $506K | $463K | $533K |
| Total Assets | $86.15M | $34.94M | $20.27M | $19.12M |
| Accounts Payable | $942K | $377K | $1.29M | $1.81M |
| Total Current Liabilities | $5.63M | $3.10M | $19.37M | $3.06M |
| Total Non-Current Liabilities | $76K | $0 | $0 | $8.86M |
| Total Liabilities | $5.70M | $3.10M | $19.37M | $11.91M |
| Total Debt (incl. Leases) | $154K | $72K | $53K | $102K |
| Common Stock | $195.4M | $116.4M | $92.91M | $71.00M |
| Retained Earnings | -$169.6M | -$131.0M | -$105.5M | -$77.28M |
| Accumulated Other Comp. Income | -$2.04M | -$4.16M | -$2.71M | -$2.79M |
| Total Stockholders' Equity | $82.04M | $33.40M | $2.22M | $7.79M |
| Total Equity | $80.45M | $31.84M | $892K | $7.21M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| Cash & Short-Term Investments | $80.56M | $33.10M | $19.34M | $18.26M |
| Accounts Receivable, Net | $716K | $258K | $154K | -- |
| Total Current Assets | $85.10M | $34.44M | $19.80M | $18.59M |
| Property, Plant & Equipment, Net | $834K | $358K | $410K | $443K |
| Total Non-Current Assets | $1.05M | $506K | $463K | $533K |
| Total Assets | $86.15M | $34.94M | $20.27M | $19.12M |
| Accounts Payable | $942K | $377K | $1.29M | $1.81M |
| Total Current Liabilities | $5.63M | $3.10M | $19.37M | $3.06M |
| Total Non-Current Liabilities | $76K | $0 | $0 | $8.86M |
| Total Liabilities | $5.70M | $3.10M | $19.37M | $11.91M |
| Total Debt (incl. Leases) | $154K | $72K | $53K | $102K |
| Common Stock | $195.4M | $116.4M | $92.91M | $71.00M |
| Retained Earnings | -$169.6M | -$131.0M | -$105.5M | -$77.28M |
| Accumulated Other Comp. Income | -$2.04M | -$4.16M | -$2.71M | -$2.79M |
| Total Stockholders' Equity | $82.04M | $33.40M | $2.22M | $7.79M |
| Total Equity | $80.45M | $31.84M | $892K | $7.21M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Net Income | -$38.61M | -$25.74M | -$28.97M | -$18.99M |
| Depreciation & Amortization | $238K | $172K | $156K | $148K |
| Stock-Based Compensation | $8.76M | $3.22M | $1.41M | $1.43M |
| Change in Receivables | -$431K | -$101K | -$104K | $230K |
| Operating Cash Flow | -$28.55M | -$29.99M | -$20.75M | -$14.40M |
| Investing Cash Flow | -$589K | -$75K | -$73K | $9.83M |
| Common Stock Issued | $73.89M | $22.85M | $15.89M | $10.64M |
| Financing Cash Flow | $76.06M | $45.78M | $21.08M | $10.80M |
| Net Change in Cash | $46.92M | $15.71M | $257K | $6.24M |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Return on Equity (ROE) | -47.0% | -76.3% | -1273.4% | -237.5% |
| Return on Assets (ROA) | -44.8% | -73.0% | -139.3% | -96.7% |
| Current Ratio | 15.12x | 11.10x | 1.02x | 6.08x |
| Quick Ratio | 14.44x | 10.75x | 1.01x | 5.97x |
| Debt to Equity | 0.00x | 0.00x | 0.02x | 0.01x |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.